# Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT04835519** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing Boren Hospital** · enrollment: 5 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Relapse Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** chimeric antigen receptor T cell

## Key facts

- **NCT ID:** NCT04835519
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-08
- **Primary completion:** 2023-05-19
- **Final completion:** 2023-05-19
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835519, "Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04835519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*